Cord tissue and placenta tissue, which are relatively new sources of stem cells when compared to cord blood, are showing great potential as Mesenchymal Cells Research gains momentum. Mesenchymal Stem Cell research includes over 50 clinical trials, using these stem cells to treat bone, cartilage, muscle, and skin disorders. New research is underway for using umbilical mesenchymal stem cells (MSCs) in the treatment of serious medical conditions in humans.
The Ontario Genomics Institute – a private not-for-profit life sciences company is investing in Toronto-based Tissue Regenerative Therapeutics (TRT) to take the next steps towards initiating human clinical trials. California’s UC Davis Health System recently received $53 million dollars in grants for research studies designed to encourage approval of human clinical trials using MSCs by the U.S. Food and Drug Administration.
Have shown in research the potential to treat debilitating conditions such as heart disease, type 1 diabetes, lung cancer, Parkinson’s Disease, and injuries to bones and cartilage.
MSCs, which are easily harvested from umbilical cord tissue and placenta tissue when a baby is born have shown in research the potential to treat debilitating conditions such as heart disease, type 1 diabetes, lung cancer, Parkinson’s Disease, and injuries to bones and cartilage. Americord is one of the few companies that offers collection of cord tissue and placenta tissue along with standard cord blood collection and it does so for an affordable price. Americord will collect and store umbilical cord blood, cord tissue and placenta tissue for $6,998 with no annual storage fee. Check the Americord website for more information.